Medical network May 5 - spring is the season of flowers in full bloom, is a good time to join with flowers, and in the garden flowers, allergic constitution of the people. Recently, allergic specialist, community hospital has a lot of the patient that is allergic to pollen, young flocculation, liuxu to come to see a doctor. 

 

Allergies are linked to individual immunity, and the recovery and bloom of everything makes spring a high season for allergies. The rapidly growing incidence of the disease has become a catalyst for the drug market, making spring a "golden season" for anti-allergic drugs. 

 

General situation of 

 

The number of allergies is high 

 

According to the world health organization, 20 to 30 percent of the average person in the world is suffering from allergies and is showing signs of annual growth. In China, the incidence of allergies is similar to that of foreign countries, with 270m people suffering from different allergies. In particular, hundreds of millions of people living in coastal or high-cold areas suffer from allergic rhinitis or allergic asthma, and the incidence of the disease is increasing rapidly. In recent years, as China's increased atmospheric environmental degradation, chemical articles for daily use, and the interference of spring pollen, skin redness, itching, macula and there are many common allergic inflammation such as respiratory system diseases. 

 

Antihistamine replacement 

 

Antihistamines varieties is widely used in clinical practice, it is mainly used for allergic disease desensitization, in the treatment of urticaria, allergic rhinitis and allergic asthma also play an important role. After years of development, the product structure of antihistamine drug is gradually improved. The new generation of antihistamines has been developed from the first generation of antihistamines to the third generation. 

 

Newly released 2017 national health insurance drug catalogue included body with antihistamine medicine, a total of 19 varieties, of which six class a drugs, diphenhydramine, chlorobenzene that sensitive, cyproheptadine, promethazine, pediatric promethazine, loratadine oral often release agent; The other is the class b drugs, including left cetirizine, loratadine, Mr Lo, bei he sting, he set in accordance with the basting, in accordance with the westin, imidazole sting and upgrading varieties. The new varieties were emetine, beestin, olo and dichlori. 

 

The sample hospital's antihistamines increased 13.72 percent 

 

According to the latest data from the HDM system, the total amount of antihistamine medicines in public hospitals in China's key cities was 476 million yuan in 2016, up 13.72 percent year on year. The rising trend in recent years, incidence of allergic disease in our country, the domestic and foreign pharmaceutical products and treatment methods of gradually, promotes the growth of antihistamine drug market in China. 

 

 

 

In 2016, the domestic main city public hospital antihistamines TOP 10 varieties are respectively in terms of loratadine, loratadine, cetirizine in accordance with the basting, left, cetirizine, loratadine, non SuoFei that, imidazole westin, in accordance with the horse and sting and lu he. 

 

varieties 

 

He is sure to be in a good position 

 

In terms of loratadine sea pharmaceutical by nanjing Shanghai and the Yangtze river pharmaceutical group, guangzhou pharmaceutical market in 2009, trade name, respectively los Mr Snow tablets and capsules. The drug is now in the market. 

 

According to the data of the HDM system, the total amount of drugs used by the public hospital in China's major urban public hospitals in 2016 reached 155.6 million yuan, up 19.22 percent from the previous year. 

 

 

 

He decided that the sample hospital was down slightly 

 

Loratadine is a long-term, no sedation, no anticholinergic effects of a new generation of antihistamine drugs, selective peripheral histamine H1 receptor function. Within the scope of the drug in the treatment of dose no drowsiness effects, suitable for tears, sneeze, allergic rhinitis, acute or chronic urticaria and other allergic skin diseases. The drug, which was first listed in Belgium in 1988, is now listed in 89 countries and sold in 15 countries as a non-prescription drug, due to its good results and small side effects. 

 

In recent years, the product has grown rapidly in international markets and is becoming the world's best-selling antihistamine. He is the third largest seller of prescription drugs in the world, and the world's top antihistamines are the first. 

 

According to the HDM system, the number of drugs used by the public hospital in the country's key urban public hospital in 2016 was 55.85 million yuan, down slightly from a year earlier. The drug has potential in the antihistamine drug market, thanks to the fact that he has a large dosage form and a class of drugs in the 2007 version of the national health care drug catalog. 

 

Ibutin: a decline of 1.44% over the previous year 

 

In accordance with the basting (Ebastine) by a Spanish Almirall company developed a new type of drug allergy, belongs to the new chlorine piperidine kind of long-term, the calm of the second generation of histamine H1 receptor antagonist. In accordance with the basting Carrie sting and its active metabolites (Carebastine) are all peripheral selective histamine H1 receptor antagonist, no obvious central nervous system function and choline. The drug and its metabolites are cannot cross the blood-brain barrier, used for seasonal, the treatment of diseases such as allergic rhinitis and chronic idiopathic urticaria, commodity called open pavilion (Kestine). 

 

According to the data of the HDM system, the total amount of drugs used in public hospitals in China's major cities in 2016 was 5.532 million yuan, down 1.44% from a year earlier. 

 

 

 

Left cetirizine: growth of 45.86% 

 

Left cetirizine, a single optical isomer of cetirizine, is the third generation of highly effective non-sedative antihistamines. At the time of the market in sitilizine, the company's patent drug, left cetirizine, has entered a deep phase of research. Left cetirizine, which was developed by Belgium in 2001, was first listed in Germany, then listed in Britain and France, with the name Xyzal. 

 

Left cetirizine is a replacement for cetirizine, ensuring that it is better than the company's position in the whole market for allergy drugs. On October 20, 2005, the CFDA approved the approval of CFDA for the name "uze" in China. 

 

We developed the technique of chiral splitting in the early years. On January 21, 2004, the CFDA first approved the production of CFDA pharmaceutical co., LTD., which is called "di dish". Then, has approved the zhejiang haili makes raw pharmaceutical left cetirizine tablets "overflow", hunan nine standard pharmaceutical capsule "to" chang, jiangsu hengrui pharmaceutical shares "flush", shandong southern shandong Bert "north" pharmacy of dispersible tablet. The CFDA has approved several companies to produce the variety, with 21 production batches. 

 

In 2016, according to HDM system data of the urban public hospitals left cetirizine medicine with a total amount of 44.43 million yuan, year-on-year growth of 45.86% last year, is the domestic antihistamines one of the highest growth rate of the drug on the market. 

 

 

 

The community is resistant to allergy drugs 

 

Cetirizine is no central sedating antihistamines, mid and late 20th century by KBC chemical group listed pharmaceutical companies for the first time, U.S. drug maker Pfizer has had its rights in the United States, commodity called Zyrtec (Ming). It was approved by the FDA in 1995 as a class B antihistamine drug, which expired in 2007 and is now used in more than 90 countries around the world. In foreign countries, cetirizine is mainly sold in the UK by glaxosmithkline, the joint chemical group of Belgium, and Japan's first three. 

 

Our country approval of cetirizine in 1991 to enter the Chinese market, and in its list of national health insurance directory, main formulations of oral tablets, capsules, tablets, oral disintegrating tablets, syrup, oral solution, and drops. To date, China has approved 63 cetirizine production papers. 

 

There are more medicines for the products of sitirizine in the country, mainly in the form of bits, sikwei, hink, limon, and hittiri. In addition, there are also applications in India for products such as prapra, ruan and the sun pharma, and the competition is intensifying. 

 

According to the HDM system, the total amount of drugs used in the 2016 national urban public hospital, citirizine, was 4.44 million yuan, up 31.64 percent year on year. Cetirizine is a class of drugs in the health care directory of most of the country's provinces, becoming the home of the community's allergy drugs and is cost-effective. 

 

 

 

The market is competitive 

 

In 1996, it was first listed in the United States, with the name Allegra. Subsequently listed in the European Union, it has been sold in many countries around the world. After more than a decade of clinical use and academic promotion, the Allegra is still a leader in the global market for prescription drugs. 

 

Currently, the CFDA has approved the registration of the non-soimana-type capsule of the U.S. Hoechst Marion Roussel in China, which is known as Telfast. Meanwhile, India's Ranbzxy Laboratories Limited is approved to enter our market, called Raltiva. 

 

Domestically made non-sodicine tablets were first listed by jiangsu hengrui pharmaceuticals, and the products were named Regis. So far, the approval has been made for the issuance of 28 non-sodi-bound batches. As the OTC market expands, competition will intensify. 

 

According to the data of the HDM system, the total amount of the drug used in public hospitals in China's major cities in 2016 was 16.49 million yuan, up 8.20% year on year. 

 

 

 

New product 

 

Lupatac, fumaric acid: the rate of drug use in the sample hospital in 2016 was over 300% 

 

He locates the list of TOP 10 antihistamines for public hospitals in China's major urban public hospitals in 2016, up more than 300 percent year on year. Fumaric acid luppa was set up by the pharmaceutical company Uriach pharmaceutical, Spain's largest pharmaceutical company, for the first time in Spain on March 15, 2003. The drug is also listed in Brazil, Portugal and Greece; In Belgium, Luxembourg, Ireland, etc. In Britain, France, South Africa and other ongoing Ⅲ clinical research; No fumaric acid luppa was registered in China. 

 

Approved on May 9, 2013, our country domestic fumaric acid palmer he listed, jiangsu Yangtze river pharmaceutical group HaiCi biological pharmaceutical API production approval, Yangtze river pharmaceutical group nanjing 'pharmaceutical get 10 mg tablet production approval. Then sichuan sea cisco pharmaceutical, Beijing sihuan division pharmaceutical and fumaric acid palmer he preparation approval, Texas bo cheng pharmaceutical fumaric acid Lou he API production approval. Currently, there are several companies in clinical trials and reported production. 

 

Lou, he as a antihistamines and platelet antagonism activated factor combination of only one allergy medications, cetirizine and the curative effect of loratadine has certain advantages, is expected to become first-line drugs for the treatment of allergic rhinitis. 

 

Mr O 'laldine: new health care is expected to grow 

 

Another antihistamine drugs produces the domestic he decide, Concorde fermentation by Japan company developed the second generation of the tranquilizing antihistamines, is the specificity, selective peripheral H1 receptor blockers, antihistamines and anti allergic activity. Orloch has been shown to be an effective drug for treating allergic rhinitis, chronic urticaria and conjunctivitis in double-blind clinical trials. 

 

In December 2000, Mr Lo he set in Japan have been approved for the treatment of allergic rhinitis, chronic urticaria, eczema, dermatitis, itching, skin pruritus, ordinary psoriasis and pleomorphic exudative erythema. The Japanese Concorde fermenting kirin has entered the Chinese market with an oral tablet, called arlo. He is the new drug to enter the national health service in 2017. Anstey has signed a deal with the Concorde fermentation kirin: in 2014, anetai has been able to acquire the exclusive right to sell in China from orotia (arlo). 

 

According to the CFDA website data, hebei Wu Yi graciousness the pharmaceutical industry, chongqing qingyang pharmaceutical and changzhou yabang pharmaceutical Mr Lo he API has approved production market, Beijing sihuan division of pharmaceutical Mr Luo he tablet and chongqing qingyang pharmaceutical industry produces the approved he tablet, capsule production. (author: Beijing jilin pharmaceutical)